This protocol addresses reactive arthritis (ReA) in the setting of anterior uveitis — a severe manifestation of ReA, second only to conjunctivitis in frequency, occurring in approximately 12% of patients with reactive arthritis.
Anterior uveitis represents a serious extra-articular involvement in ReA. Its severity and recurrent nature require dedicated therapeutic consideration, particularly when standard measures prove insufficient.
For recurrent uveitis in reactive arthritis that has not responded adequately to other therapies, an anti-TNF biologic approach is used — the full protocol specifies the clinical criteria, agent selection, and monitoring framework.
Anterior uveitis is a severe manifestation of ReA, second to conjunctivitis in frequency, affecting about 12% of patients with ReA.
Anti-TNF showed high efficacy and a good safety profile in the treatment of recurrent uveitis, refractory to other therapies.
View source ↗